naltrexone has been researched along with buprenorphine, naloxone drug combination in 36 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 17 (47.22) | 24.3611 |
| 2020's | 19 (52.78) | 2.80 |
| Authors | Studies |
|---|---|
| Hasson, A; Hillhouse, M; Lindblad, R; Ling, W; McCormack, J; Mooney, LJ; Nielsen, S; Saxon, A; Stablein, D; Thomas, C | 1 |
| Bawor, M; Bonner, A; Daiter, J; Dennis, BB; Desai, D; Marsh, DC; Naji, L; Pare, G; Plater, C; Samaan, Z; Thabane, L; Varenbut, M; Worster, A | 1 |
| Chalk, M; Lubran, R; Mark, TL; McCance-Katz, EF; Richardson, J | 1 |
| Willyard, C | 1 |
| Ang, A; Annon, J; Brigham, GS; Church, S; Dawes, M; Drexler, K; Hasson, A; Hillhouse, MP; Knox, PC; Korthuis, PT; Lawson, W; Ling, W; Liu, DS; Matthews, AG; McCormack, J; Mooney, LJ; Ross, S; Rotrosen, J; Saxon, AJ; Schuman, C; Sparenborg, S; Swafford, W; Thomas, CM; Wiest, K | 1 |
| Gaulen, Z; Kunøe, N; Latif, ZE; Opheim, A; Sharma-Haase, K; Solli, KK; Tanum, L | 1 |
| Bailey, GL; Brigham, GS; Cohen, AJ; Fishman, M; Lee, JD; Lindblad, R; Ling, W; Liu, D; May, J; Mpa, PN; Nunes, EV; Rotrosen, J; Salazar, D; Shmueli-Blumberg, D; Stablein, D | 1 |
| Bailey, G; Brigham, G; Caplan, A; Farkas, S; Fishman, M; Lee, JD; Novo, P; Nunes, EV; Rotrosen, J; Segal, A; Sisti, D | 1 |
| Leff, JA; Linas, BP; Morgan, JR; Schackman, BR; Walley, AY | 1 |
| Bachrach, K; Bailey, GL; Bhatt, S; Farkas, S; Fishman, M; Gauthier, P; Hodgkins, CC; King, J; Lee, JD; Lindblad, R; Liu, D; Matthews, AG; May, J; Novo, P; Nunes, EV; Peavy, KM; Ross, S; Rotrosen, J; Salazar, D; Schkolnik, P; Shmueli-Blumberg, D; Stablein, D; Subramaniam, G | 1 |
| Benth, JŠ; Krajci, P; Kunoe, N; Latif, ZE; Opheim, A; Sharma-Haase, K; Solli, KK; Tanum, L | 2 |
| Hunter, SB; McCullough, CM; Ober, AJ; Osilla, K; Setodji, CM; Watkins, KE | 1 |
| Barocas, JA; Saitz, R | 1 |
| Krajci, P; Kunoe, N; Latif, ZE; Opheim, A; Šaltyte Benth, J; Sharma-Haase, K; Solli, KK; Tanum, L | 1 |
| Klein, AA; Seppala, MD | 1 |
| Ashford, RD; Bergman, BG; Kelly, JF | 1 |
| Barbosa-Leiker, C; Burlew, K; Campbell, ANC; Fitzpatrick, S; Greenfield, SF; Nunes, EV; Pavlicova, M; Rotrosen, J; Ruglass, LM; Scodes, J | 1 |
| Burlew, AK; Campbell, ANC; Haeny, AM; Montgomery, L; Nunes, E; Pavlicova, M; Rotrosen, J; Scodes, J | 1 |
| Jalali, A; Jeng, PJ; Lee, JD; Leff, JA; McCollister, KE; Murphy, SM; Novo, P; Nunes, EV; Rotrosen, J; Ryan, DA; Schackman, BR | 1 |
| Acevedo-Mackey, D; Acharjee, N; Akhtar, K; Al-Buriahi, MS; Amandi, A; An, Y; Anjum, NA; Asgari, Q; Badiei, B; Baez Vasquez, AY; Bagley, GD; Bahreini, MS; Bajelan, S; Baluja, MQ; Barbieri, MA; Batalha, MA; Bettiol, H; Bhattarai, U; Biset, JC; Bjerg, M; Björnsson, BT; Boag, AM; Borthwick, MS; Boukhris, I; Bragança, MLBM; Breves, JP; Britz-McKibbin, P; Broaddus, RR; Burnell, JE; Camargo, CA; Campo, M; Carlsen, KL; Catchpole, B; Cavalli, L; Chai, C; Chanakya, HN; Chang, AYH; Chantada, A; Chen, W; Chen, X; Chen, Y; Cheng, ZL; Chenoweth, DA; Chhetri, S; Coelho, CCNDS; Coker, ES; Cole, MA; Coniglio, A; Connor, TR; Corbishley, A; D'Arienzo, M; da Silva, AAM; Dai, Y; de Oliveira, BR; Dignac, MF; Dong, A; Dottino, JA; Duo, J; Einarsdottir, IE; Ekanayake, EMDNK; El Fels, L; El Hayany, B; El Shahawy, O; Elliott, RJR; Fabrizi, E; Farkas, K; Fellman, B; Fenoglio, D; Ferrario, M; Flögel, F; Fujiogi, M; Gamage, BD; Ganson, KT; Gao, X; Gärtner, S; Gautam, A; Gautam, S; Gaze, WH; Gosse, JA; Graham, DW; Graham, PA; Guastella, G; Guerrero, S; Gul, M; Guo, B; Guo, X; Gupta, VK; Hafidi, M; Halland, A; Han, W; Hardisty, M; Hasegawa, K; Hess, ST; Heydari, R; Hillary, LS; Holm, R; Huang, L; Jaleh, B; Jayasundara, JASB; Ji, X; Jiang, L; Jones, DL; Kac, G; Kebaili, I; Kelley, JB; Kelum, SHP; Kennedy, LJ; Khan, NA; Khazalpour, S; Khuntia, HK; Kinney, MS; Kommedal, Ø; Koomhin, P; Krawczyk, N; Kæstel, T; Lakmal, MAC; Li, H; Li, K; Li, R; Li, S; Li, W; Li, X; Li, Y; Liang, L; Lin, Y; Lippo, E; Liu, B; Liu, F; Liu, J; Liu, X; Liu, Y; Lodha, D; Loose, DS; López-Meza, P; Lu, F; Lu, KH; Lu, Y; Luo, Y; Ma, B; Malham, SK; Masood, A; Matan, N; McCormick, SD; McDonald, JE; McKenzie, LJ; Melendez, BD; Mikaeili, F; Mir, IR; Mirjalili, MH; Moreno, KP; Moura, IB; Müller, S; Nagata, JM; Nasri, A; Nasrollahzadeh, M; Navarro-Jiménez, E; Nie, E; Nielsen, CU; Nielsen, S; Nøhr, MK; Obeng, B; Odetayo, AA; Ortiz-Barrios, M; Ozgen, C; Pan, X; Parisi, ML; Paskavitz, AL; Patel, AK; Pedersen, M; Pontarollo, N; Potts, CM; Price, C; Pu, Y; Quénéa, K; Rahimi Khonakdari, M; Rather, BA; Raut, P; Regish, AM; Reible, DD; Rezadoost, H; Rizzati, M; Roviello, GN; Roviello, V; Rumpel, C; Sang, J; Sangroula, S; Saraiva, MDCP; Sarker, A; Sayyed, MI; Segoshi, A; Sehar, Z; Shao, X; Shaw, D; Shaw, L; Shekhawat, NS; Shim, JK; Shokouhimehr, M; Short, A; Soliman, PT; Songsamoe, S; Springer-Miller, RH; Stenstad, T; Strobl, E; Sun, R; Syme, H; Thai, L; Tian, G; Tofighi, B; Tonguc, B; Tuyiringire, D; Ulaganathan, N; Ulvestad, E; Varacca, A; Vergalli, S; Verma, DK; Villmones, HC; Wang, D; Wang, H; Wang, J; Wang, L; Wang, M; Wang, S; Wang, Y; Wang, Z; Weedon-Fekjær, H; Weller, SR; West, BE; Wilcox, MH; Wu, W; Wufuer, R; Xia, S; Xiang, H; Xu, H; Yan, L; Yang, RK; Yang, Y; Yates, MS; Ye, Q; Yin, H; Yin, Y; Yuan, Y; Yucesan, M; Yue, W; Zeng, W; Zhang, C; Zhang, D; Zhang, H; Zhang, L; Zhang, Q; Zhang, Y; Zhou, B; Zhou, Y; Zhu, Y; Zhu, Z | 1 |
| Fishman, M; Lee, JD; Nunes, E; Pavlicova, M; Rotrosen, J; Scodes, J; Wenzel, K | 1 |
| Choo, TH; Gryczynski, J; Mitchell, MM; Nunes, EV; O'Grady, KE; Pavlicova, M; Rotrosen, J; Schwartz, RP; Stitzer, ML | 1 |
| Costello, E; Novo, P; Nunes, EV; Rotrosen, J; Shulman, M; Weiss, R | 1 |
| Campbell, ANC; Fishman, M; Nunes, E; Pavlicova, M; Rotrosen, J; Scodes, J; Wenzel, K | 1 |
| Campbell, ANC; Lee, JD; Novo, P; Nunes, EV; Pavlicova, M; Rotrosen, J; Scodes, JM | 1 |
| Benth, JŠ; Fadnes, LT; Gaulen, Z; Kunøe, N; Latif, ZE; Opheim, A; Solli, KK; Tanum, L | 1 |
| Cinemre, B; Coşkun, MN; Erdoğan, A; Kulaksızoğlu, B; Kuloğlu, MM; Topcuoğlu, M | 1 |
| Choo, TH; Langleben, DD; Nunes, EV; Pavlicova, M; Rotrosen, J; Shulman, M; Wang, AL | 1 |
| Graham, DP; Hamon, SC; Hillhouse, M; Kosten, TR; Lawson, WB; Ling, W; Nielsen, DA; Nielsen, EM; Rotrosen, J; Saxon, AJ; Settles-Reaves, BD; Shmueli-Blumberg, D; Shores-Wilson, K; Trivedi, MH; Walker, R | 1 |
| Campbell, ANC; Choo, TH; Cook, RR; Lee, JD; Nunes, EV; Pavlicova, M; Rotrosen, J; Shulman, M; Tsui, JI | 1 |
| Bolton, J; Hoang, H; Laiteerapong, N; Marsh, J; Murugesan, M; Nocon, R; Peterson, L; Pollack, H | 1 |
| Díaz, I; Luo, SX; Nunes, EV; Rotrosen, J; Rudolph, KE; Williams, NT | 1 |
| Batki, SL; Baxley, C; Becker, W; Borsari, B; Herbst, E; Manuel, JK; Pennington, D; Reavis, JV; Seal, K | 1 |
| Barbosa-Leiker, C; Burlew, K; Campbell, ANC; Choo, TH; Greenfield, SF; Kathryn McHugh, R; Mennenga, S; Nunes, EV; Paschen-Wolff, M; Pavlicova, M; Rotrosen, J; Ruglass, LM | 1 |
| Benth, JŠ; Fadnes, LT; Gaulen, Z; Kloster, PS; Kunøe, N; Opheim, A; Solli, KK; Tanum, L | 1 |
3 review(s) available for naltrexone and buprenorphine, naloxone drug combination
| Article | Year |
|---|---|
Topics: Acyclic Monoterpenes; Adipose Tissue; Adolescent; Adult; Aged; Aged, 80 and over; Air Pollutants; Air Pollutants, Occupational; Amino Acid Transport Systems; Analgesics, Opioid; Animals; Anti-Bacterial Agents; Anti-Infective Agents; Arthrobacter; Bacteria; Bacteriological Techniques; Benzaldehydes; Biodegradation, Environmental; Biofilms; Biological Transport; Biomarkers; Biomass; Bioreactors; Body Composition; Body Mass Index; Brassica; Brazil; Buprenorphine; Buprenorphine, Naloxone Drug Combination; Caco-2 Cells; Cadmium; Calcium; Calcium Carbonate; Calcium Channels; Catalysis; Cell Degranulation; Cell Line; Cell Membrane; Chitosan; Chromatography, High Pressure Liquid; Chromium; Cobalt; Cohort Studies; Colony Count, Microbial; Composting; Copper; COVID-19; Cross-Sectional Studies; Cytoplasm; Delayed-Action Preparations; Diabetes Mellitus, Type 2; Diarrhea; Diethylhexyl Phthalate; Dose-Response Relationship, Drug; Drug Implants; Drug Stability; Drug Synergism; Electroplating; Endometrial Neoplasms; Endometrium; Environmental Monitoring; Environmental Restoration and Remediation; Estradiol; Estrogens; Feces; Female; Food Microbiology; Food Preservation; Fruit and Vegetable Juices; Gasotransmitters; Gastrointestinal Diseases; Gastrointestinal Microbiome; Gene Expression Regulation, Developmental; Genetic Predisposition to Disease; Glutathione; Gold; Graphite; Growth Hormone; Harm Reduction; Hot Temperature; Humans; Hydrocortisone; Hydrogen; Hydrogen Peroxide; Hydrogen Sulfide; Hydrogen-Ion Concentration; Ileum; Imidazoles; Injections, Intraperitoneal; Insecticides; Insulin-Like Growth Factor Binding Protein 1; Insulin-Like Growth Factor Binding Protein 2; Insulin-Like Growth Factor Binding Protein 5; Insulin-Like Growth Factor I; Intestinal Absorption; Light; Lignin; Liver; Magnetics; Male; Manganese; Mast Cells; Melanoma; Membrane Potentials; Metals; Methadone; Microbial Viability; Microplastics; Microscopy, Electron, Scanning; Microscopy, Electron, Transmission; Middle Aged; Mitochondrial Swelling; Molecular Dynamics Simulation; Monophenol Monooxygenase; Morocco; Naloxone; Naltrexone; Nanocomposites; Nanomedicine; Nanoparticles; Narcotic Antagonists; Neonicotinoids; Nitric Oxide; Nitro Compounds; Nitrogen; Nitrogen Compounds; Obesity; Obesity, Abdominal; Occupational Exposure; Ontario; Opiate Substitution Treatment; Opioid-Related Disorders; Oryza; Overweight; Oxidative Stress; Oxides; Oxygen; Perception; Photoelectron Spectroscopy; Plants; Plastics; Point Mutation; Polychlorinated Biphenyls; Polycyclic Aromatic Hydrocarbons; Potassium; Premenopause; Prodrugs; Prospective Studies; Protons; Pyrolysis; Qualitative Research; Rats; Rats, Sprague-Dawley; Reactive Oxygen Species; Resins, Synthetic; Rhodamines; Risk Factors; ROC Curve; Salmo salar; SARS-CoV-2; Seawater; Severity of Illness Index; Sewage; Social Media; Soil; Soil Microbiology; Soil Pollutants; Spectroscopy, Fourier Transform Infrared; Spectrum Analysis, Raman; Staining and Labeling; Stainless Steel; Steel; Stress, Physiological; Substance Abuse Treatment Centers; Symporters; T-Lymphocytes; Toluene; Triclosan; Ultraviolet Rays; Waist Circumference; Waste Disposal, Fluid; Wastewater; Water Purification; Welding; X-Ray Diffraction; Young Adult | 2020 |
Prior National Drug Abuse Treatment Clinical Trials Network (CTN) opioid use disorder trials as background and rationale for NIDA CTN-0100 "optimizing retention, duration and discontinuation strategies for opioid use disorder pharmacotherapy (RDD)".
Topics: Analgesics, Opioid; Buprenorphine; Buprenorphine, Naloxone Drug Combination; Humans; Naltrexone; Narcotic Antagonists; Nitrosamines; Opiate Substitution Treatment; Opioid-Related Disorders; United States | 2021 |
Effects of buprenorphine on opioid craving in comparison to other medications for opioid use disorder: A systematic review of randomized controlled trials.
Topics: Analgesics, Opioid; Buprenorphine; Buprenorphine, Naloxone Drug Combination; Craving; Delayed-Action Preparations; Humans; Methadone; Naltrexone; Narcotic Antagonists; Opioid-Related Disorders; Randomized Controlled Trials as Topic | 2023 |
20 trial(s) available for naltrexone and buprenorphine, naloxone drug combination
| Article | Year |
|---|---|
Cocaine use reduction with buprenorphine (CURB): rationale, design, and methodology.
Topics: Administration, Sublingual; Adolescent; Adult; Aged; Buprenorphine; Buprenorphine, Naloxone Drug Combination; Cocaine-Related Disorders; Cognitive Behavioral Therapy; Combined Modality Therapy; Double-Blind Method; Drug Combinations; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Naloxone; Naltrexone; Narcotic Antagonists; Opioid-Related Disorders; Treatment Outcome; Young Adult | 2013 |
Buprenorphine + naloxone plus naltrexone for the treatment of cocaine dependence: the Cocaine Use Reduction with Buprenorphine (CURB) study.
Topics: Administration, Oral; Adult; Analgesics, Opioid; Buprenorphine, Naloxone Drug Combination; Cocaine-Related Disorders; Cognitive Behavioral Therapy; Delayed-Action Preparations; Double-Blind Method; Female; Humans; Injections, Intramuscular; Male; Middle Aged; Naltrexone; Narcotic Antagonists; Treatment Outcome | 2016 |
Design of a randomized controlled trial of extended-release naltrexone versus daily buprenorphine-naloxone for opioid dependence in Norway (NTX-SBX).
Topics: Adult; Buprenorphine, Naloxone Drug Combination; Delayed-Action Preparations; Female; Follow-Up Studies; Humans; Injections, Intramuscular; Male; Naltrexone; Narcotic Antagonists; Norway; Opioid-Related Disorders | 2016 |
NIDA Clinical Trials Network CTN-0051, Extended-Release Naltrexone vs. Buprenorphine for Opioid Treatment (X:BOT): Study design and rationale.
Topics: Buprenorphine, Naloxone Drug Combination; Comparative Effectiveness Research; Cost-Benefit Analysis; Delayed-Action Preparations; Female; Humans; Injections, Intramuscular; Male; Naltrexone; Narcotic Antagonists; National Institute on Drug Abuse (U.S.); Opioid-Related Disorders; Socioeconomic Factors; United States | 2016 |
Comparative effectiveness of extended-release naltrexone versus buprenorphine-naloxone for opioid relapse prevention (X:BOT): a multicentre, open-label, randomised controlled trial.
Topics: Administration, Oral; Adult; Buprenorphine, Naloxone Drug Combination; Delayed-Action Preparations; Female; Humans; Injections, Intramuscular; Male; Naltrexone; Narcotic Antagonists; Opioid-Related Disorders; Research Design | 2018 |
Patient predictors of substance use disorder treatment initiation in primary care.
Topics: Adult; Age Factors; Alcoholism; Buprenorphine, Naloxone Drug Combination; Cognitive Behavioral Therapy; Cooperative Behavior; Female; Health Services Accessibility; Humans; Logistic Models; Male; Middle Aged; Motivational Interviewing; Multivariate Analysis; Naltrexone; Opioid-Related Disorders; Primary Health Care; Psychotherapy, Brief; Sex Factors | 2018 |
Anxiety, Depression, and Insomnia Among Adults With Opioid Dependence Treated With Extended-Release Naltrexone vs Buprenorphine-Naloxone: A Randomized Clinical Trial and Follow-up Study.
Topics: Administration, Oral; Adolescent; Adult; Anxiety; Buprenorphine, Naloxone Drug Combination; Comorbidity; Delayed-Action Preparations; Depression; Female; Follow-Up Studies; Humans; Injections, Intramuscular; Male; Middle Aged; Naltrexone; Opioid-Related Disorders; Sleep Initiation and Maintenance Disorders; Young Adult | 2019 |
No increased pain among opioid-dependent individuals treated with extended-release naltrexone or buprenorphine-naloxone: A 3-month randomized study and 9-month open-treatment follow-up study.
Topics: Adult; Buprenorphine, Naloxone Drug Combination; Chronic Pain; Female; Humans; Male; Middle Aged; Naltrexone; Narcotic Antagonists; Norway; Opiate Substitution Treatment; Opioid-Related Disorders; Pain Measurement | 2019 |
Trajectory classes of opioid use among individuals in a randomized controlled trial comparing extended-release naltrexone and buprenorphine-naloxone.
Topics: Adult; Analgesics, Opioid; Buprenorphine, Naloxone Drug Combination; Delayed-Action Preparations; Female; Humans; Male; Middle Aged; Naltrexone; Narcotic Antagonists; Opioid-Related Disorders; Treatment Outcome | 2019 |
Extended-release naltrexone versus buprenorphine-naloxone to treat opioid use disorder among black adults.
Topics: Adult; Black or African American; Buprenorphine, Naloxone Drug Combination; Delayed-Action Preparations; Female; Humans; Injections, Intramuscular; Male; Naltrexone; Narcotic Antagonists; Opioid-Related Disorders | 2020 |
Health-related quality of life and opioid use disorder pharmacotherapy: A secondary analysis of a clinical trial.
Topics: Adult; Analgesics, Opioid; Buprenorphine, Naloxone Drug Combination; Female; Humans; Male; Middle Aged; Naltrexone; Opiate Substitution Treatment; Opioid-Related Disorders; Quality of Life | 2020 |
An alternative analysis of illicit opioid use during treatment in a randomized trial of extended-release naltrexone versus buprenorphine-naloxone: A per-protocol and completers analysis.
Topics: Administration, Sublingual; Adult; Ambulatory Care; Analgesics, Opioid; Buprenorphine, Naloxone Drug Combination; Delayed-Action Preparations; Female; Humans; Injections, Intramuscular; Male; Naltrexone; Narcotic Antagonists; Opioid-Related Disorders | 2021 |
Examination of Correlates of OUD Outcomes in Young Adults: Secondary Analysis From the XBOT Trial.
Topics: Aged; Analgesics, Opioid; Buprenorphine, Naloxone Drug Combination; Delayed-Action Preparations; Humans; Naltrexone; Opiate Substitution Treatment; Opioid-Related Disorders; Young Adult | 2021 |
Sublingual Buprenorphine-Naloxone Compared With Injection Naltrexone for Opioid Use Disorder: Potential Utility of Patient Characteristics in Guiding Choice of Treatment.
Topics: Administration, Sublingual; Adult; Buprenorphine, Naloxone Drug Combination; Delayed-Action Preparations; Female; Humans; Injections, Intramuscular; Male; Middle Aged; Naltrexone; Narcotic Antagonists; Opioid-Related Disorders; Treatment Outcome; Young Adult | 2021 |
Risk of Relapse Among Opioid-Dependent Patients Treated With Extended-Release Naltrexone or Buprenorphine-Naloxone: A Randomized Clinical Trial.
Topics: Adult; Analgesics, Opioid; Buprenorphine, Naloxone Drug Combination; Delayed-Action Preparations; Female; Follow-Up Studies; Humans; Injections, Intramuscular; Male; Naltrexone; Narcotic Antagonists; Opioid-Related Disorders; Recurrence | 2021 |
Baseline- and treatment-associated pain in the X:BOT comparative effectiveness study of extended-release naltrexone versus buprenorphine-naloxone for OUD.
Topics: Buprenorphine, Naloxone Drug Combination; Chronic Pain; Delayed-Action Preparations; Humans; Injections, Intramuscular; Naltrexone; Narcotic Antagonists; Opioid-Related Disorders; Prospective Studies | 2022 |
Moderation of buprenorphine therapy for cocaine dependence efficacy by variation of the Prodynorphin gene.
Topics: Buprenorphine; Buprenorphine, Naloxone Drug Combination; Cocaine; Cocaine-Related Disorders; Delayed-Action Preparations; Enkephalins; Humans; Injections, Intramuscular; Naltrexone; Narcotic Antagonists; Opioid-Related Disorders; Protein Precursors | 2022 |
Methamphetamine/amphetamine use over time among persons with opioid use disorders treated with buprenorphine/naloxone versus extended-release naltrexone.
Topics: Buprenorphine; Buprenorphine, Naloxone Drug Combination; Delayed-Action Preparations; Humans; Injections, Intramuscular; Methamphetamine; Naltrexone; Narcotic Antagonists; Opioid-Related Disorders | 2022 |
Clinical and psychosocial outcomes by sex among individuals prescribed buprenorphine-naloxone (BUP-NX) or extended-release naltrexone (XR-NTX) for opioid use disorder.
Topics: Buprenorphine, Naloxone Drug Combination; Delayed-Action Preparations; Female; Humans; Male; Naltrexone; Opioid-Related Disorders; Treatment Outcome | 2023 |
Risk of relapse to non-opioid addictive substances among opioid dependent patients treated with an opioid receptor antagonist or a partial agonist: A randomized clinical trial.
Topics: Analgesics, Opioid; Buprenorphine; Buprenorphine, Naloxone Drug Combination; Chronic Disease; Delayed-Action Preparations; Female; Humans; Injections, Intramuscular; Male; Naltrexone; Narcotic Antagonists; Opioid-Related Disorders; Recurrence | 2023 |
13 other study(ies) available for naltrexone and buprenorphine, naloxone drug combination
| Article | Year |
|---|---|
The effectiveness of opioid substitution treatments for patients with opioid dependence: a systematic review and multiple treatment comparison protocol.
Topics: Buprenorphine; Buprenorphine, Naloxone Drug Combination; Heroin; Humans; Methadone; Naloxone; Naltrexone; Narcotics; Opiate Substitution Treatment; Opioid-Related Disorders; Research Design; Systematic Reviews as Topic | 2014 |
Medicaid coverage of medications to treat alcohol and opioid dependence.
Topics: Acamprosate; Alcohol Deterrents; Alcohol-Related Disorders; Buprenorphine, Naloxone Drug Combination; Humans; Insurance Coverage; Medicaid; Methadone; Naltrexone; Narcotic Antagonists; Narcotics; Opioid-Related Disorders; Taurine; United States | 2015 |
Pharmacotherapy: Quest for the quitting pill.
Topics: Animals; Behavior, Addictive; Buprenorphine; Buprenorphine, Naloxone Drug Combination; Clinical Trials as Topic; Cocaine-Related Disorders; Counseling; Dopamine; Drug Discovery; Drug Industry; Humans; Ibogaine; Lobeline; Molecular Targeted Therapy; Naloxone; Naltrexone; Oligopeptides; Opioid-Related Disorders; Pleasure; Rats; Receptors, Nicotinic; Reward; Substance-Related Disorders; Tobacco Use Disorder; Vaccines; Vesicular Monoamine Transport Proteins | 2015 |
Ethical and clinical safety considerations in the design of an effectiveness trial: A comparison of buprenorphine versus naltrexone treatment for opioid dependence.
Topics: Administration, Sublingual; Buprenorphine, Naloxone Drug Combination; Comparative Effectiveness Research; Counseling; Delayed-Action Preparations; Ethics, Research; Humans; Informed Consent; Injections, Intramuscular; Naltrexone; Narcotic Antagonists; Opioid-Related Disorders; Patient Preference; Patient Safety; Prisoners; Randomized Controlled Trials as Topic; Vulnerable Populations | 2016 |
Injectable naltrexone, oral naltrexone, and buprenorphine utilization and discontinuation among individuals treated for opioid use disorder in a United States commercially insured population.
Topics: Adult; Age Factors; Analgesics, Opioid; Buprenorphine; Buprenorphine, Naloxone Drug Combination; Drug Administration Routes; Female; Humans; Insurance Claim Review; Male; Medication Adherence; Naltrexone; Narcotic Antagonists; Opioid-Related Disorders; Practice Patterns, Physicians'; Prevalence; Sex Factors; United States | 2018 |
Effectiveness, safety and feasibility of extended-release naltrexone for opioid dependence: a 9-month follow-up to a 3-month randomized trial.
Topics: Adult; Buprenorphine, Naloxone Drug Combination; Cohort Studies; Delayed-Action Preparations; Feasibility Studies; Female; Humans; Injections, Intramuscular; Male; Naltrexone; Narcotic Antagonists; Norway; Opioid-Related Disorders; Prospective Studies; Randomized Controlled Trials as Topic; Treatment Outcome | 2018 |
Being Explicit About Decisions: Prescribe Medications for Opioid Use Disorder on the Basis of Proven Effectiveness, Not Beliefs.
Topics: Analgesics, Opioid; Buprenorphine, Naloxone Drug Combination; Cost-Benefit Analysis; Humans; Naltrexone; Opioid-Related Disorders; Recurrence | 2019 |
Medication-assisted treatment for opioid use disorder within a 12-step based treatment center: Feasibility and initial results.
Topics: Adult; Ambulatory Care; Behavior Therapy; Buprenorphine, Naloxone Drug Combination; Combined Modality Therapy; Day Care, Medical; Feasibility Studies; Female; Follow-Up Studies; Humans; Male; Naltrexone; Narcotic Antagonists; Opiate Substitution Treatment; Opioid-Related Disorders; Outcome Assessment, Health Care; Patient Compliance; Prospective Studies; Residential Treatment | 2019 |
Attitudes toward opioid use disorder medications: Results from a U.S. national study of individuals who resolved a substance use problem.
Topics: Adolescent; Adult; Attitude; Buprenorphine, Naloxone Drug Combination; Female; Humans; Male; Methadone; Middle Aged; Naltrexone; Narcotic Antagonists; Opiate Substitution Treatment; Opioid-Related Disorders; Prevalence; United States; Young Adult | 2020 |
Young Adults Have Worse Outcomes Than Older Adults: Secondary Analysis of a Medication Trial for Opioid Use Disorder.
Topics: Adolescent; Adult; Aged; Buprenorphine, Naloxone Drug Combination; Delayed-Action Preparations; Female; Humans; Male; Naltrexone; Narcotic Antagonists; Opioid-Related Disorders; Young Adult | 2020 |
Comparison of naltrexone implant and oral buprenorphine-naloxone in the treatment of opiate use disorder.
Topics: Buprenorphine; Buprenorphine, Naloxone Drug Combination; Delayed-Action Preparations; Female; Humans; Injections, Intramuscular; Naltrexone; Narcotic Antagonists; Opiate Alkaloids; Opioid-Related Disorders; Prospective Studies; Retrospective Studies | 2022 |
Health care use and spending for Medicaid patients diagnosed with opioid use disorder receiving primary care in Federally Qualified Health Centers and other primary care settings.
Topics: Analgesics, Opioid; Benzodiazepines; Buprenorphine; Buprenorphine, Naloxone Drug Combination; Cross-Sectional Studies; Delivery of Health Care; Humans; Medicaid; Methadone; Naltrexone; Opioid-Related Disorders; Primary Health Care; United States | 2022 |
Optimally Choosing Medication Type for Patients With Opioid Use Disorder.
Topics: Analgesics, Opioid; Buprenorphine; Buprenorphine, Naloxone Drug Combination; Humans; Methadone; Naltrexone; Narcotic Antagonists; Opioid-Related Disorders | 2023 |